Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Serina Therapeutics (SER) Interest & Investment Income (2018 - 2022)

Serina Therapeutics (SER) has disclosed Interest & Investment Income for 5 consecutive years, with -$863000.0 as the latest value for Q2 2022.

  • Quarterly Interest & Investment Income fell 214.96% to -$863000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Jun 2022, down 143.83% year-over-year, with the annual reading at -$1.1 million for FY2021, 171.53% down from the prior year.
  • Interest & Investment Income hit -$863000.0 in Q2 2022 for Serina Therapeutics, down from -$571000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $39000.0 in Q3 2018 to a low of -$863000.0 in Q2 2022.
  • Historically, Interest & Investment Income has averaged -$165176.5 across 5 years, with a median of -$65000.0 in 2020.
  • Biggest five-year swings in Interest & Investment Income: rose 22.22% in 2019 and later tumbled 1687.5% in 2020.
  • Year by year, Interest & Investment Income stood at $32000.0 in 2018, then tumbled by 175.0% to -$24000.0 in 2019, then tumbled by 658.33% to -$182000.0 in 2020, then tumbled by 62.09% to -$295000.0 in 2021, then crashed by 192.54% to -$863000.0 in 2022.
  • Business Quant data shows Interest & Investment Income for SER at -$863000.0 in Q2 2022, -$571000.0 in Q1 2022, and -$295000.0 in Q4 2021.